.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Colorcon
Cantor Fitzgerald
Healthtrust
McKinsey
QuintilesIMS
Chinese Patent Office
Chubb
Johnson and Johnson
UBS

Generated: September 22, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
Abstract:Novel N-(3-hydroxy-4-pipridinyl)benzamides and derivatives thereof, said compounds being used as stimulators of the motility of the gastro-intestinal system.
Inventor(s): Van Daele; Georges (Turnhout, BE)
Assignee: Janssen Pharmaceutica N.V. (Beerse, BE)
Filing Date:Jun 11, 1990
Application Number:07/535,939
Claims:1. A compound of the formula: ##STR59## the pharmaceutically acceptable acid addition salts thereof, the stereochemically isomeric forms, and the pharmaceutically acceptable quaternary ammonium salts thereof, wherein:

the substituents in the 3 and 4 positions in the piperidine ring have the cis configuration;

R.sup.1 represents a member selected from the group consisting of hydrogen, lower alkyl, (Ar.sup.1)lower alkyl, and lower alkylcarbonyl;

R.sup.2 represents hydrogen;

R.sup.3, R.sup.4, and R.sup.5 each independently represent hydrogen, lower alkyl, lower alkyloxy, halo, hydroxy, amino, nitro, mono- or di(lower alkyl)amino, lower alkylcarbonylamino, lower alkylcarbonyl, lower alkylcarbonyloxy, aminosulfonyl, and lower alkylsulfonyl; and

L represents a group of the formula:

wherein r represents an integer of from 1 to 6 inclusive and Ar.sup.2 represents a member selected from the group consisting of naphthalenyl and pyridinyl,

wherein in the foregoing Ar.sup.1 represents a member selected from the group consisting of phenyl being optionally substituted with up to 3 substituents each independently selected from the group consisting of halo, hydroxy, lower alkyl, lower alkyloxy, aminosulfonyl, lower alkylcarbonyl, nitro, trifluoromethyl, amino, aminocarbonyl, phenylcarbonyl wherein said phenyl may be optionally substituted with up to 3 halo atoms, and thienyl substituted with halo or lower alkyl.

2. A compound according to claim 1 wherein R.sup.3 , R.sup.4, and R.sup.5 are, each independently, selected from the group consisting of halo, amino, mono- and di(lower alkyl)amino, and lower alkyloxy.

3. A compound according to claim 2 wherein R.sup.3 represents methoxy, R.sup.4 represents amino or methylamino, and R.sup.5 represents chloro, wherein said R.sup.3, R.sup.4, and R.sup.5 are attached to the phenyl ring in the 2-, 4-, and 5-positions, respectively.

4. A compound according to claim 3 wherein r represents 1 and Ar.sup.2 represents pyridinyl.

5. A compound according to claim 1 wherein the compound is cis-4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-pyridinylmethyl)-4-piperidin yl]benzamide.

6. A pharmaceutical composition in unit dosage form comprising per dosage unit an effective gastro-intestinal motility stimulating amount of a compound as described in claim 1, the pharmaceutically acceptable acid addition salts thereof, the stereochemically isomeric forms, and the pharmaceutically acceptable quaternary ammonium salts thereof.

7. The pharmaceutical composition of claim 6 wherein R.sup.3, R.sup.4, and R.sup.5 are, each independently, selected from the group consisting of halo, amino, mono- and di(lower alkyl)amino, and lower alkyloxy.

8. The pharmaceutical composition of claim 7 wherein R.sup.3 represents methoxy, R.sup.4 represents amino or methylamino, and R.sup.5 represents chloro, wherein said R.sup.3, R.sup.4, and R.sup.5 are attached to the phenyl ring in the 2-, 4-, and 5-positions, respectively.

9. The pharmaceutical composition of claim 8 wherein r represents 1 and Ar.sup.2 represents pyridinyl.

10. The pharmaceutical composition of claim 6 wherein the compound is cis-4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-(2-pyridinylmethyl)-4-piperi dinyl]benzamide.

11. A method of stimulating the motility of the gastro-intestinal system which comprises the systemic administration to vertebrates of an effective gastro-intestinal motility stimulating amount of a compound as described in claim 1, the pharmaceutically acceptable acid addition salts thereof, the stereochemically isomeric forms, and the pharmaceutically acceptable quaternary ammonium salts thereof.

12. A method according to claim 11 wherein R.sup.3, R.sup.4, and R.sup.5 are, each independently, selected from the group consisting of halo, amino, mono- and di(lower alkyl)amino, and lower alkyloxy.

13. A method according to claim 12 wherein R.sup.3 represents methoxy, R.sup.4 represents amino or methylamino, and R.sup.5 represents chloro, wherein said R.sup.3, R.sup.4, and R.sup.5 are attached to the phenyl ring in the 2-, 4-, and 5-positions, respectively.

14. A method according to claim 13 wherein r represents 1 and Ar.sup.2 represents pyridinyl.

15. A method according to claim 11 wherein the compound is cis-4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-(2pyridinylmethyl)-4-piperid inyl]benzamide.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Cerilliant
Baxter
Queensland Health
Daiichi Sankyo
Merck
Accenture
Cipla
Julphar
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot